Derek DiRocco

CIK: 0001792061

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (46.2%)

Compensation grants

Other (G, F, J, C, D, …)7 (53.8%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (5)

BBTX

Bambusa Therapeutics, Inc.

Director

ACRV

Acrivon Therapeutics, Inc.

Director

MLYS

Mineralys Therapeutics, Inc.

Director

EVMN

Evommune, Inc.

Director

ETNB

89bio, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (13 total)

ACRV
Acrivon Therapeutics, Inc.
Jun 17, 2026
Award(A)
Stock Option (Right to Buy)
Direct
20.3K shares-
ACRV
Acrivon Therapeutics, Inc.
May 18, 2026
Award(A)
Direct
9.4K shares-
MLYS
Mineralys Therapeutics, Inc.
Feb 19, 2026
Award(A)
Direct
6.2K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Indirect
12.5K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
25K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
45.2K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
56.4K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
27.4K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
7K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Indirect
7K shares-
ACRV
Acrivon Therapeutics, Inc.
Jun 13, 2025
Award(A)
Stock Option (Right to Buy)
Direct
20.3K shares-
MLYS
Mineralys Therapeutics, Inc.
Feb 13, 2025
Award(A)
Stock Option
Direct
32.9K shares-
ETNB
89bio, Inc.
Feb 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
56.4K shares-

		Type	Shares	Price		Ownership
Jun 17, 2026	ACRV Acrivon Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	20,275	-	-	Direct
May 18, 2026	ACRV Acrivon Therapeutics, Inc.	Award(A)	9,366	-	$0	Direct
Feb 19, 2026	MLYS Mineralys Therapeutics, Inc.	Award(A)	6,200	-	$0	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	12,500	-	-	Indirect
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	25,000	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	45,150	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	56,400	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	27,400	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	7,000	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	7,000	-	-	Indirect
Jun 13, 2025	ACRV Acrivon Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	20,275	-	-	Direct
Feb 13, 2025	MLYS Mineralys Therapeutics, Inc.	Award(A) Stock Option	32,900	-	-	Direct
Feb 3, 2025	ETNB 89bio, Inc.	Award(A) Stock Option (Right to Buy)	56,400	-	-	Direct

1-13 of 13 transactions

About DiRocco Derek

DiRocco Derek (SEC CIK 0001792061) files insider reports with the SEC as Director of Bambusa Therapeutics, Inc. (BBTX), Director of Acrivon Therapeutics, Inc. (ACRV) and Director of Mineralys Therapeutics, Inc. (MLYS). Signal8 also holds filings tied to 2 other companies.

Signal8 holds 9 ownership filings by DiRocco Derek (2 Form 3, 7 Form 4), filed between Feb 5, 2025 and Oct 29, 2026. Those filings report 13 transactions, from Feb 3, 2025 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on DiRocco Derek's filings is in BOSTON, MA.

Recent filings by DiRocco Derek

Jun 17, 2026: Grant or award of ACRV derivative securities (Form 4, code A).
May 18, 2026: Grant or award of ACRV shares (Form 4, code A).
Feb 19, 2026: Grant or award of MLYS shares (Form 4, code A).
Oct 30, 2025: Disposition to issuer transactions of ETNB derivative securities (7 lines, Form 4, code D).
Jun 13, 2025: Grant or award of ACRV derivative securities (Form 4, code A).

Other insiders filing for Bambusa Therapeutics, Inc. (BBTX)

How to read Form 4 transaction codes